Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 7Terminated 5Completed 3Active not recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 3Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Interventional × futibatinib × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT02693535 2026-05-15

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05727176 2025-12-29

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡